AI-Enhanced Molecular Modeling Shortens Path to Market of New Drugs

Biosimulytics focuses on developing a platform that enables biopharma companies to shorten the time to market of new drug compounds by simulating lead optimization, one of the most challenging steps of the drug development process. This process relies on tedious laboratory experiments to crystallize and further characterize candidate drug molecules. Biosimulytics’ patented platform computes the most stable crystal structure, making drug development faster, more cost-effective and with less risk.